BrightEdge is the American Cancer Society’s impact investment arm that, through equity investment seeks to translate groundbreaking cancer research into commercially accessible solutions, deepen social impact through patient first technologies, while generating financial returns that help sustain ongoing American Cancer Society research and programs in more than 5,000 local communities.